[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-382621-105":59,"doc-detail-382621-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","double-faecal-immunochemical-testing-in-patients-with-symptoms-suspicious-of-colorectal-cancer","Double faecal immunochemical testing in patients with symptoms suspicious of colorectal cancer","","Faecal immunochemical test (FIT)-directed pathways for symptomatic colorectal cancer rely on single-test thresholds, yet a single FIT shows limited sensitivity around 10 µg haemoglobin per g faeces. The study evaluates diagnostic performance of one FIT versus two FITs in succession in sequential symptomatic cohorts. All patients underwent investigation regardless of test results, enabling comparison of sensitivity, missed cancers, bowel pathology, and faecal Hb correlation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/double-faecal-immunochemical-testing-in-patients-with-symptoms-suspicious-of-colorectal-cancer/382621/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/double-faecal-immunochemical-testing-in-patients-with-symptoms-suspicious-of-colorectal-cancer/382621.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does the study compare single FIT versus double FIT in symptomatic patients?","Question",{"text":112,"@type":113},"One cohort received a single FIT before investigation, while another cohort received two FITs in succession before investigation. All patients were investigated regardless of the test outcome.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What impact did a second FIT have on missed colorectal cancers and significant bowel pathology?",{"text":117,"@type":113},"The second FIT reduced cancers missed by the first FIT by 50.0% and reduced missed significant bowel pathology by 30.0%.",{"name":119,"@type":110,"acceptedAnswer":120},"How do sensitivity results differ between single and double FIT?",{"text":121,"@type":113},"Single FIT sensitivity for colorectal cancer was 84.1%, versus 96.6% for double FIT. For significant bowel pathology, sensitivity increased from 67.4% with single FIT to 83.0% with double FIT.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},382621,1790444041,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","BJS, 2023, 110, 471–480  \n[https://doi.org/10.1093/bjs/znad016](https://doi.org/10.1093/bjs/znad016)  \nAdvance Access Publication Date: 14 February 2023  \nOriginal Article  \nDouble faecal immunochemical testing in patients with symptoms suspicious of colorectal cancer  \nA. D. Gerrard1,2 , Y. Maeda1,3 , J. Miller2, F. Gunn2, E. Theodoratou1,4, C. Noble5, L. Porteous6, S. Glancy7, P. MacLean7, R. Pattenden8, M. G. Dunlop1,9, and F. V. N. Din1,2,*; Edinburgh Colorectal Group2  \n1Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK  \n2Department of Colorectal surgery, Western General Hospital, Edinburgh, UK 3Department of Surgery, Queen Elizabeth University Hospital, Glasgow, UK 4Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK 5Department of Gastroenterology, Western General Hospital, Edinburgh, UK 6Lead GP for Cancer and Palliative Care, NHS Lothian, Edinburgh, UK 7Department of Radiology, Western General Hospital, Edinburgh, UK 8Department of Biochemistry, Western General Hospital, Edinburgh, UK  \n9UK Colon Cancer Genetics Group, Medical Research Council Human Genetics Unit, Medical Research Council Institute of Genetics & Cancer, Western General Hospital, The University of Edinburgh, Edinburgh, UK  \n*Correspondence to: Farhat Din, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK  \n(e-mail: [farhat.din@ed.ac.uk](farhat.din@ed.ac.uk))  \nMembers of the Edinburgh Colorectal Group are co-authors of this study and are listed under the heading Collaborators.  \nAbstract  \nBackground: Faecal immunochemical test (FIT)-directed pathways based on a single test have been implemented for symptomatic patients. However, with a single test, the sensitivity is 87 per cent at 10 µg haemoglobin (Hb) per g faeces. This aims of this study were to define the diagnostic performance of a single FIT, compared with double FIT in symptomatic populations.  \nMethods: Two sequential prospective patient cohorts referred with symptoms from primary care were studied. Patients in cohort 1 were sent a single FIT, and those in cohort 2 received two tests in succession before investigation. All patients were investigated, regardless of having a positive or negative test (threshold 10 µg Hb per g) .  \nResults: In cohort 1, 2260 patients completed one FIT and investigation. The sensitivity of single FIT was 84.1 (95 per cent c.i. 73.3 to 91.8) per cent for colorectal cancer and 67.4 (61.0 to 73.4) per cent for significant bowel pathology. In cohort 2, 3426 patients completed at least one FIT, and 2637 completed both FITs and investigation. The sensitivity of double FIT was 96.6 (90.4 to 99.3) percent for colorectal cancer and 83.0 (77.4 to 87.8) per cent for significant bowel pathology. The second FIT resulted in a 50.0 per cent reduction in cancers missed by the first FIT, and 30.0 per cent for significant bowel pathology. Correlation between faecal Hb level was only modest (rS = 0.58), and 16.8 per cent of double tests were discordant, 11.4 per cent in patients with colorectal cancer and 18.3 per cent in those with significant bowel pathology.  \nConclusion: FIT in patients with high-risk symptoms twice in succession reduces missed significant colorectal pathology and has an acceptable workload impact.  \nIntroduction  \nEarly detection strategies for colorectal cancer, in parallel with preventive measures, are key to improving survival1. Colorectal symptoms are a common presentation in primary care; of those referred to secondary care only 3–5 per cent of patients are diagnosed with colorectal cancer2. The number of suspected colorectal cancer referrals to secondary care is increasing  \nwithout a proportionate increase in early cancer diagnoses3.  \nFaecal immunochemical test (FIT) is commonly used to prioritize investigation in symptomatic patients and outperforms symptomatic assessment alone in identifying colorectal c","cbCaiaADpai68T35","https://ap.wps.com/l/cbCaiaADpai68T35","pdf",248891,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"How does the study compare single FIT versus double FIT in symptomatic patients?\",\"answer\":\"One cohort received a single FIT before investigation, while another cohort received two FITs in succession before investigation. All patients were investigated regardless of the test outcome.\"},{\"question\":\"What impact did a second FIT have on missed colorectal cancers and significant bowel pathology?\",\"answer\":\"The second FIT reduced cancers missed by the first FIT by 50.0% and reduced missed significant bowel pathology by 30.0%.\"},{\"question\":\"How do sensitivity results differ between single and double FIT?\",\"answer\":\"Single FIT sensitivity for colorectal cancer was 84.1%, versus 96.6% for double FIT. For significant bowel pathology, sensitivity increased from 67.4% with single FIT to 83.0% with double FIT.\"}]","Double faecal immunochemical testing in patients with symptoms suspicious of colorectal cancer | PDF",1790251400,25]